Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
By B. Eichhorst, R. Busch, G. Hopfinger, R. Pasold, M. Hensel, C. Steinbrecher, Siegfried Siehl, U. Jäger, M. Bergmann, S. Stilgenbauer and 6 more. Blood, 2005
626 citations recorded by the source corpus.
Subfields: Genetics, Immunology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/16f947a4cd7ca081467b148a04d97514c4ffc002
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Immunology
In Pathology and Forensic Medicine
Citations in the corpus
- Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. (2008, neutral): “2 or more upper limit normal (%) 6 (2) 2 (33)”
- TP53 mutation and survival in chronic lymphocytic leukemia. (2010, methodology): “Details on the trial were previously reported.(22) In brief, diagnosis, treatment requirement, and response evaluation were based on the criteria established by the National Cancer Institute–sponsored Working Group guidelines.”
- From pathogenesis to treatment of chronic lymphocytic leukaemia (2010, background): “However, to date none of the randomized trials of combination chemotherapy showed a survival benefit for a specific treatment in CLL when only the treatment arms were compare”
- Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. (2014, neutral): “(%) 16/203 (8) 10/96 (10) 9/196 (5) 10/97 (10) 22/295 (7) 20/287 (7)”